Skip to content

Everolimus

Afinitor, Afinitor Disperz, Zortress, Votubia (everolimus) is a small molecule pharmaceutical. Everolimus was first approved as Afinitor on 2009-03-30. It has been approved in Europe to treat breast neoplasms, pancreatic neoplasms, renal cell carcinoma, and tuberous sclerosis. The pharmaceutical is active against serine/threonine-protein kinase mTOR. In addition, it is known to target Cytochrome P450. Afinitor's patents are valid until 2028-07-01 (FDA).
Trade Name Afinitor, Votubia
Common Name Everolimus
Indication breast neoplasms, pancreatic neoplasms, renal cell carcinoma, tuberous sclerosis
Drug Class Immunosuppressives: immunosuppressant, rapamycin derivatives
Everolimus
Get full access now